![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Genetica+ Gets CE-IVD Mark for Blood Test for Depression Treatments
Genetica+ Gets CE-IVD Mark for Blood Test for Depression Treatments
Genetica+ has gained the CE-IVD mark for its NeuroKaire blood test which helps determine the optimal antidepressant treatment for major depressive disorder.
The test analyzes a blood sample for biomarkers using artificial intelligence and machine learning techniques.
In a recent 12-week study, the product demonstrated “unprecedented accuracy” in predicting drug response, the company said.
The Israel-based company is focused on developing solutions for psychiatric and neurological diseases.
Upcoming Events
-
18Jul
-
21Oct